MarketWire -- London, UK; Brentwood, TN, US: 8 August 2008 - Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and cancer, in accordance with Listing Rule 3.5.6, notifies the following details in respect of a block listing for the Company’s 6% Unsecured Convertible Loan Notes:
